WHO II-III级弥漫性胶质瘤组织学与遗传学亚型的灌注与扩散MRI特征
本研究纳入65例WHO II-III级弥漫性胶质瘤患者,比较2007年组织学亚型与2016年遗传学亚型间灌注和扩散MRI特征的差异。结果显示ADC在分子亚型间差异显著(p=0.0016),多变量模型区分IDHWT与IDHMUT的AUC为0.84,在IDHMUT肿瘤中区分1p/19q+与1p/19q-的AUC为0.80。作者认为联合rCBV、ADC、T2高信号体积和强化表现可能有助于无创识别弥漫性胶质瘤的遗传学亚型。
要点
- 纯星形细胞瘤与纯少突胶质细胞瘤间rCBV和ADC无显著差异
- ADC在分子亚型间差异显著,尤其IDHWT与IDHMUT/1p19q+之间
- 多变量模型区分IDHWT与IDHMUT的AUC为0.84,区分1p/19q状态AUC为0.80
核心结论
- ADC在区分2016年WHO遗传学亚型方面优于2007年WHO组织学分类。
- 联合rCBV、ADC、T2高信号体积和强化表现可能有助于无创识别弥漫性胶质瘤遗传学亚型。
研究设计与样本
- 纳入65例WHO II-III级弥漫性胶质瘤患者,具有2007年组织学诊断、1p/19q状态和IDH1突变状态。
- 在T2高信号病灶内估算中位相对脑血容量(rCBV)和表观扩散系数(ADC)。
- 采用Bootstrap假设检验比较按WHO分级和2007或2016分类方案划分的胶质瘤亚群。
- 采用多变量逻辑回归模型区分1p19q+与1p19q-的WHO II-III级胶质瘤。
主要发现
- 纯星形细胞瘤与纯少突胶质细胞瘤组织学亚型间rCBV和ADC均无显著差异。
- ADC在分子亚型间差异显著(p=0.0016),尤其IDHWT与IDHMUT/1p19q+之间(p=0.0013)。
- IDHMUT/1p19q+ III级胶质瘤中位ADC较高;IDHWT III级胶质瘤rCBV较高而ADC较低;IDHMUT/1p19q-的rCBV和ADC值居中,与其II级对应肿瘤相似。
- 多变量逻辑回归模型区分IDHWT与IDHMUT WHO II和III级胶质瘤的AUC为0.84(p<0.0001,敏感度74%,特异度79%)。
- 在IDHMUT WHO II-III级胶质瘤中,另一多变量逻辑回归模型区分1p19q+与1p19q-的AUC为0.80(p=0.0015,敏感度64%,特异度82%)。
临床怎么用
- 作者认为联合rCBV、ADC、T2高信号体积和强化表现可能有助于无创识别弥漫性胶质瘤的遗传学亚型。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The value of perfusion and diffusion-weighted MRI in differentiating histological subtypes according to the 2007 WHO glioma classification scheme (i.e. astrocytoma vs. oligodendroglioma) and genetic subtypes according to the 2016 WHO reclassification (e.g. 1p/19q co-deletion and IDH1 mutation status) in WHO grade II and III diffuse gliomas remains controversial. In the current study, we describe unique perfusion and diffusion MR signatures between histological and genetic glioma subtypes. Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study. In all patients, median relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) were estimated within T2 hyperintense lesions. Bootstrap hypothesis testing was used to compare subpopulations of gliomas, separated by WHO grade and 2007 or 2016 glioma classification schemes. A multivariable logistic regression model was also used to differentiate between 1p19q+ and 1p19q- WHO II-III gliomas. Neither rCBV nor ADC differed significantly between histological subtypes of pure astrocytomas and pure oligodendrogliomas. ADC was significantly different between molecular subtypes (p = 0.0016), particularly between IDHWT and IDHMUT/1p19q+ (p = 0.0013). IDHMUT/1p19q+ grade III gliomas had higher median ADC; IDHWT grade III gliomas had higher rCBV with lower ADC; and IDHMUT/1p19q- had intermediate rCBV and ADC values, similar to their grade II counterparts. A multivariable logistic regression model was able to differentiate between IDHWT and IDHMUT WHO II and III gliomas with an AUC of 0.84 (p < 0.0001, 74% sensitivity, 79% specificity). Within IDHMUT WHO II-III gliomas, a separate multivariable logistic regression model was able to differentiate between 1p19q+ and 1p19q- WHO II-III gliomas with an AUC of 0.80 (p = 0.0015, 64% sensitivity, 82% specificity). ADC better differentiated between genetic subtypes of gliomas according to the 2016 WHO guidelines compared to the classification scheme outlined in the 2007 WHO guidelines based on histological features of the tissue. Results suggest a combination of rCBV, ADC, T2 hyperintense volume, and presence of contrast enhancement together may aid in non-invasively identifying genetic subtypes of diffuse gliomas.
引用
- Leu K, Ott GA, Lai A, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017. PMID: 28547590. doi:10.1007/s11060-017-2506-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。